Regeneron Pharmaceuticals, Inc. has been named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co., a human genetics and biotechnology company. Regeneron intends to acquire 23andMe’s Personal Genome Service (PGS), Total Health and Research Services business lines, together with its Biobank and associated assets, for $256 million. Subject to bankruptcy court and regulatory approvals and other customary closing conditions, the transaction ...